International Cancer Research Conference
March 24-26, 2025 | Singapore
Cancer Drugs Market
The sales of cancer drugs and related services by entities (organizations, sole traders, and partnerships) that create oncology drugs to diagnose and treat all forms of malignancies constituting the oncology drugs market. This industry comprises manufactures of medications for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain cancer, and other cancers with chemotherapy, surgery, and radiotherapy. Drugs are developed by the pharmaceutical industry to diagnose, cure, or prevent diseases. Since 2015, the worldwide oncology drugs market has grown at a compound annual growth rate (CAGR) of 9.8%, reaching over $167.9 billion in 2019. At a CAGR of 9.7%, the market is predicted to rise modestly from $201.1 billion in 2021 to $284.5 billion in 2023. The market is predicted to level out in 2025, reaching $284.5 billion and $412.9 billion by 2030.
- Strong pipeline of drugs
- Drug market: current and expected trends
- Oncology market during pandemic
- FDA rules and regulations
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Jianhua Luo
University of Pittsburgh, United States
Kaushala Prasad Mishra
Asian Association for Radiation Research (AARR), India
Ibrahim El Bayoumy
Consultant of public health-Ministry of Health, Kuwait
Özlem Terzi
Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Turkey
Andrea González Báez
Autonomous University of Nuevo Leon, MexicoSubmit your abstract Today
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title :
Jianhua Luo, University of Pittsburgh, United States
Title : Biosensor-based detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Principles of oral rehabilitation in H&N cancer patients
Pietro Salvatori, Independent H&N Surgeon, Italy
Title :
Marika Crohns, Impactful Innovations Management Consultants LLC, United Arab Emirates